Article

Tissue adhesive reduces pterygium recurrence after excision with conjunctival autografting

In patients undergoing primary pterygium excision with conjunctival autografting, use of a fibrin tissue adhesive (Tisseel VH Fibrin Sealant) to adhere the graft can improve long-term outcomes by lowering recurrence rates, according to the findings of a retrospective case series presented by investigators from the University of California-Irvine.

In patients undergoing primary pterygium excision with conjunctival autografting, use of a fibrin tissue adhesive (Tisseel VH Fibrin Sealant) to adhere the graft can improve long-term outcomes by lowering recurrence rates, according to the findings of a retrospective case series presented by investigators from the University of California-Irvine.

The study compared recurrence rates in 27 eyes that had surgery using the tissue adhesive and a comparator group of 20 eyes in which the conjunctival autograft was secured using 8-0 Vicryl. All surgeries were performed by a single surgeon and received the same corticosteroid regimen postoperatively. The patients were predominantly non-Hispanic whites, and the two study groups were well matched with respect to demographic features and pterygium size.

During a minimum follow-up of 6 months, the recurrence rate was significantly lower in the tissue adhesive group compared with the sutured group, 3.7% versus 20%, respectively. All recurrences occurred within the first 3 to 3.5 months after surgery, and the patients who developed a recurrence were younger on average than those who remained recurrence-free.

"Our study found a lower rate of recurrence in a patient population that was predominantly white and residing in southern California," said Marjan Farid, MD. "However, it is a retrospective review and relatively small. Further studies are needed in larger sample sizes and should look at effects of the tissue adhesive in various racial-ethnic groups as well as when used in combination with amniotic membrane transplants or mitomycin-C."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.